Sanofi/GSK/Haleon: cancer fears prove hard to stomach
Shares of GlaxoSmithKline, Sanofi and the new GSK spin-off, Haleon, all fell sharply last week

Stress causes “ulcers and heartburn”, said Lex in the FT. “Now the treatment of these afflictions is causing anxiety for investors.”
Shares of GlaxoSmithKline, Sanofi and the new GSK spin-off, Haleon, all fell sharply last week – shedding tens of billions of dollars – as investors took fright over the reported carcinogenic risk posed by the over-the-counter drug Zantac. Damages, if awarded, could be as high as $45bn, according to Morgan Stanley. And since rights of the over-the-counter version of Zantac have been transferred repeatedly, “it is unclear where any liabilities might sit”.
The issue of whether Zantac (the brand name for a drug called ranitidine) generates a probable carcinogen called NDMA has been building in the background for years, said Julianna Tatelbaum on CNBC: the drug was formally pulled from shelves in 2020, but legal proceedings have focused minds. The first of more than 2,000 cases begins in the US this month.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
The pharmas believe their legal position is strong, said Fierce Pharma. “The overwhelming weight of the scientific evidence supports the conclusion that there is no increased cancer risk,” stated GSK. Even if that risk is demonstrated, it will be “tough” to prove that the companies “knew of the danger and failed to warn customers” before withdrawing Zantac.
The litigation creates an awkward situation for GSK and the recently floated Haleon, said Alistair Osborne in The Times. If liability becomes an issue, it could mean “an unseemly legal dust-up between two companies that were in the same group four weeks ago”.
Precedent suggests investors should certainly remain wary, said Lex. The Bayer/Roundup weedkiller saga – which ultimately cost the German pharma at least $16bn – “shows it is easy to draw a line under claims prematurely”.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
-
A running list of RFK Jr.'s controversies
In Depth The man atop the Department of Health and Human Services has had no shortage of scandals over the years
By Brigid Kennedy
-
Film reviews: Sinners and The King of Kings
Feature Vampires lay siege to a Mississippi juke joint and an animated retelling of Jesus' life
By The Week US
-
Music reviews: Bon Iver, Valerie June, and The Waterboys
Feature "Sable, Fable," "Owls, Omens, and Oracles," "Life, Death, and Dennis Hopper"
By The Week US
-
Mental health: a case of overdiagnosis?
Talking Point Issues at 'the milder end of the spectrum' may be getting wrongly pathologised
By The Week UK
-
Fighting against fluoride
Feature A growing number of communities are ending water fluoridation. Will public health suffer?
By The Week US
-
Five years on: How Covid changed everything
Feature We seem to have collectively forgotten Covid’s horrors, but they have completely reshaped politics
By The Week US
-
Why are more young people getting bowel cancer?
The Explainer Alarming rise in bowel-cancer diagnoses in under-50s is puzzling scientists
By Elizabeth Carr-Ellis, The Week UK
-
Bird flu: The viral threat pushing up egg prices
Feature
By The Week US
-
Five medical breakthroughs of 2024
The Explainer The year's new discoveries for health conditions that affect millions
By Adrienne Wyper, The Week UK
-
New Alzheimer's drug rejected: is Nice being nasty?
Talking Point Health watchdog has announced lecanemab will be denied to NHS patients on cost grounds
By The Week UK
-
The great baby bust
The Explainer The fertility rate is falling sharply in the UK and across the world, a trend with major economic and societal consequences
By The Week UK